PARP inhibitors are used in targeted cancer therapy, often in cancers that are particularly reliant on PARP for DNA repair. They are most effective in cancers with homologous recombination deficiencies, such as BRCA1/2-mutated cancers. These drugs are approved for use in the treatment of ovarian cancer, breast cancer, prostate cancer, and pancreatic cancer. Clinical trials are ongoing to explore their effectiveness in other types of cancer and in combination with other treatments such as chemotherapy and immunotherapy.
